Nitazoxanide - Genfit
Alternative Names: G 1090N; NTZ - Genfit; Repurposed nitazoxanide - GenfitLatest Information Update: 25 Sep 2025
At a glance
- Originator Genfit
- Developer Genfit; Pinnacle Clinical Research
- Class Amides; Anthelmintics; Anti-inflammatories; Antidiarrhoeals; Antifibrotics; Antiprotozoals; Antivirals; Benzamides; Hepatoprotectants; Nitro compounds; Phenylacetates; Small molecules; Thiazoles
- Mechanism of Action EIF-2 kinase modulators; HN protein inhibitors; Oxidoreductase inhibitors; Receptor protein-tyrosine kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hepatic fibrosis
- No development reported Liver failure
Most Recent Events
- 22 Sep 2025 Genfit plans a proof of concept clinical trial for Liver Failure in the first half of 2026
- 07 Aug 2025 Genfit plans a phase I trial for Liver Failure (In volunteers) in August 2025 (PO, Capsules) (NCT07110441)
- 06 Feb 2025 Genfit plans a clinical trial for Liver failure in the first quarter of 2025